First Clinical Trial of Pluripotent Stem Cell-Derived Neural Stem Cells for Huntington’s Disease Highlighted at ISSCR 2026

Phase 1b/2a study marks an important milestone in the development of regenerative medicine approaches for Huntington's disease An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease was presented today at the ISSCR 2026 Annual Meeting. The Phase 1b/2a REGEN4HD study represents a significant translational milestone…